Cell line name |
MDA-MB-231-MEK-R |
Accession |
CVCL_V403 |
Resource Identification Initiative |
To cite this cell line use: MDA-MB-231-MEK-R (RRID:CVCL_V403) |
Comments |
Group: Triple negative breast cancer (TNBC) cell line. Population: Caucasian. Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
Sequence variations |
- Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
|
Disease |
Breast adenocarcinoma (NCIt: C5214) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0062 (MDA-MB-231) |
Sex of cell |
Female |
Age at sampling |
51Y |
Category |
Cancer cell line |
Publications | PubMed=22402123; DOI=10.1158/1535-7163.MCT-11-1010 Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P., Haverty P.M., Soriano R., Forrest W.F., Heldens S., Chen H.-F., Toy K., Ha C., Zhou W., Song K., Friedman L.S., Amler L.C., Hampton G.M., Moffat J., Belvin M.P., Lackner M.R. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11:1143-1154(2012) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_V403
|
Encyclopedic resources |
Wikidata; Q54904605
|
Polymorphism and mutation databases |
Cosmic; 1927243
|
Entry history |
Entry creation | 16-Apr-2014 |
Last entry update | 05-Oct-2023 |
Version number | 20 |
---|